The Massachusetts Medical Society notes that access to mifepristone remains unchanged at this time, allowing for continuity of care and avoiding immediate disruptions for patients.
Mifepristone has been used for more than 25 years and is supported by extensive clinical evidence demonstrating its safety and effectiveness for early pregnancy termination and the management of miscarriage. It is widely recognized as a standard component of evidence-based medical care.
Maintaining access—including through telehealth and mail dispensing—supports timely, patient-centered care and helps reduce delays that may increase clinical risk. Ensuring reliable access to essential medications is important for maintaining quality and safety in medical practice.
Given ongoing variability in the regulatory environment, the Society emphasizes the importance of stable, evidence-based policies that support consistent access to medically indicated treatments.
The Massachusetts Medical Society commends state leaders, including Governor Maura Healey and Attorney General Andrea Campbell, for their continued leadership in safeguarding access to reproductive health care for patients in Massachusetts and remains committed to advancing patient safety, supporting evidence-based care, and ensuring that clinical decision-making is guided by the best available scientific data.
-Olivia Liao, MD, President, Massachusetts Medical Society
